First-Line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Women With Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of First-Line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial
JAMA Oncol 2021 Apr 22;[EPub Ahead of Print], C Falandry, F Rousseau, MA Mouret-Reynier, F Tinquaut, D Lorusso, J Herrstedt, AM Savoye, L Stefani, E Bourbouloux, R Sverdlin, V D'Hondt, A Lortholary, PE Brachet, A Zannetti, E Malaurie, L Venat-Bouvet, O Trédan, L Mourey, E Pujade-Lauraine, G FreyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.